Clinical Trials

Our programs focus on innovations that have the potential to deliver highly impactful
therapies for unmet medical needs and drive differentiated therapeutic benefits for patients.

Phase 1/2a, open label, multi-center study of CLN-081 in patients with NSCLC (non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy. Status: Recruiting
Study ID: NCT04036682